This article first appeared on GuruFocus .
Novo Nordisk ( NYSE:NVO ), the diabetes-and-obesity heavyweight, fell approximately 2% to $46.625 Friday as Wegovy's pill rollout reached its first European Union market. Germany now joins the United States, Britain and the United Arab Emirates in selling the once-daily oral weight-loss treatment.
German pharmacies are expected to price the pill near Wegovy injections, with doses ranging from roughly 170 to 280. Novo says Wegovy already commands 90% of the oral obesity market and expects tablets to capture more than one-third of GLP-1 usage by 2030. That is the real opportunity: win patients who want weight loss without the needle while protecting revenue per prescription.
The valuation picture makes the selloff harder to ignore. Novo's $46.625 share price sits 57.51% below its $109.74 GF Value, signaling a steep market discount as investors question whether oral Wegovy can revive growth against Eli Lilly. Germany is now a crucial proving groundstrong prescription uptake and patient retention could turn convenience into Novo's next major competitive weapon.
